1-3 of 3
Adeboye Henry Adewoye
Close
Sort by
Journal Articles

Exposure-Response of Idelalisib Administered in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Chronic Lymphocytic Leukemi

Vinay Manu Daryani, PharmD, Shringi Sharma, PhD, Guan Xing, PhD, Jeffrey Silverman, PhD, Adeboye Henry Adewoye, MD, Anita Mathias, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5344.
https://doi.org/10.1182/blood.V130.Suppl_1.5344.5344
Published: 2017
Journal Articles

Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

Andrew D. Zelenetz, Jennifer R. Brown, Julio Delgado, Herbert Eradat, Paolo Ghia, Abraham Jacob, Wojciech Jurczak, Javier Loscertales, Donald MacDonald, Franck Morschhauser, Javier De la Serna, Mazyar Shadman, Christopher Pocock, Adeboye Henry Adewoye, Yeonhee Kim, David Simpson, Stephan Stilgenbauer
Journal: Blood
Blood (2016) 128 (22): 231.
https://doi.org/10.1182/blood.V128.22.231.231
Published: 2016
Journal Articles

A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials

Laurie H Sehn, MD, Michael Hallek, Wojciech Jurczak, Jennifer R. Brown, Paul M. Barr, John Catalano, Steven E. Coutre, MD, Richard R. Furman, Nicole Lamanna, Ysebaert Loïc, Andrew D. Zelenetz, Jeffrey P. Sharman, Sven DeVos, Adeboye Henry Adewoye, Yeonhee Kim, Ian W. Flinn, MD PhD, Gilles A. Salles
Journal: Blood
Blood (2016) 128 (22): 3705.
https://doi.org/10.1182/blood.V128.22.3705.3705
Published: 2016